KRAS and cancer: A total of 7 gene sets out of 50 were enriched within the hallmarks of cancer sets comprising of epithelial-mesenchymal transition (Fig. 5A, n = 196, ES = 0.61, P < .001), G2M checkpoint (Fig. 5B, n = 187, ES = 0.60, P < .001), allograft rejection (Fig. 5C, n = 195, ES = 0.58, P < .001), E2F targets (Fig. 5D, n = 192, ES = 0.57, P < .001), coagulation (Fig. 5E, n = 137, ES = 0.51, P < .001), KRAS signaling up (Fig. 5F, n = 193, ES = 0.47, P < .001), and inflammatory response (Fig. 6A, n = 198, ES = 0.53, P < .001).